Biological Features and History of Discovery
Chlamydophila pneumoniae is a unique species with a weak genetic relationship (low DNA homology) to other Chlamydia species. The primary morphological feature of this microorganism is the shape of its elementary bodies. Due to specific expansion of the periplasmic space, they acquire a pear-shaped or lanceolate appearance. The pathogen possesses a characteristic species-specific antigen in its structure.
Cultivating this bacterium in laboratory conditions is extremely difficult. It does not grow on simple nutrient media and is capable of multiplying exclusively inside living cells, for which specialized cultures—such as HeLa and HEp-2 cell lines—are used.
The history of studying this pathogen began relatively recently:
- 1965 (Taiwan): The first atypical strain was isolated from a child with trachoma.
- 1983 (USA): A similar microorganism was isolated from a patient with pharyngitis.
- 1989: Researcher J. Grayston grouped these strains isolated from respiratory diseases and proposed the modern name C. pneumoniae.
Epidemiology and Pathogenesis
Respiratory chlamydiosis is an anthroponosis—an infection where humans are the sole reservoir and source of transmission. Chlamydiae can persist in the upper respiratory tract of carriers for long periods, frequently causing asymptomatic carriage.
The transmission mechanism is airborne droplet infection. The infection is widespread (particularly common in Northern Europe), and susceptibility to it is high in individuals over 20 years of age.
Pathogenesis is driven by the strict tropism of the pathogen for respiratory epithelium. The portal of entry is the mucous membrane of the upper respiratory tract. The bacterium attaches to cells (epitheliocytes) with the pointed end of its lanceolate body and penetrates inside. Active intracellular multiplication of the microorganism inevitably leads to the death of the infected cell. Massive destruction of the epithelium triggers severe inflammation of the lung tissue. Additionally, cell breakdown products and chlamydial toxins exert a systemic damaging effect on other organs.
Clinical Presentation and Role in Systemic Pathology
The infection most commonly manifests as pharyngitis, bronchitis, and pneumonia, while sinusitis is diagnosed less frequently. The disease presents as a typical "atypical pneumonia", which clinically cannot be distinguished from infections caused by mycoplasmas, legionellae, or respiratory viruses.
Characteristic features of the clinical course:
- Indolent onset without sharp temperature spikes (temperature elevation is mild).
- In the early stages, patients complain of nasopharyngeal inflammation and hoarseness.
- Subclinical and asymptomatic forms are frequently recorded.
Of particular scientific and clinical interest is the involvement of C. pneumoniae in the development of somatic diseases. The microorganism has been reliably detected in atheromatous plaques on the inner lining of the aorta and coronary arteries, suggesting it acts as one of the etiologic factors in the development of atherosclerosis. Furthermore, a potential link between the pathogen and the onset of bronchial asthma, sarcoidosis, arthritis, and meningoencephalitis is under discussion.
Diagnostic Methods and Treatment Approaches
Due to the challenges of isolating the microorganism, the culture method (sputum, lung tissue, or throat swab culture) is rarely used. Serological testing serves as the foundation of laboratory diagnostics.
Complement fixation tests (CFT), enzyme-linked immunosorbent assay (ELISA), and microimmunofluorescence (the most specific test) are used to detect antibodies.
- In primary infection, the appearance of IgM class antibodies serves as a marker.
- In reinfections (secondary infections), a fourfold rise in IgG titer or a single IgG titer > 1:512 is documented.
- In adults, the detection of IgA is considered the most reliable criterion for active infection.
Polymerase chain reaction (PCR) for bacterial DNA detection and indirect immunofluorescence assay (IFA) for specific chlamydial MOMP antigen detection are used as molecular and rapid diagnostic methods.
Because the pathogen resides intracellularly, macrolides and tetracyclines—antibiotics capable of achieving high intracellular concentrations—are used for treatment. Specific prophylaxis (vaccination) has not been developed, and lasting immunity is not conferred after recovery.